# Belite Bio

Belite Bio is an Asset Manager based in San Diego, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** San Diego, United States
- **Region:** North America
- **Address:** San Diego, CA, United States
- **Founded:** 2018
- **Assets under management:** Undisclosed
- **Website:** belitebio.com

## Regulatory record

- **Reports private funds:** No

## About

Founded in 2018 by Tom Lin, Belite Bio operates as a clinical-stage biotech focused on developing treatments for degenerative retinal diseases. The firm is structured around Tinlarebant, an oral retinol-binding protein 4 antagonist. The underlying premise targets the accumulation of toxic vitamin A byproducts in the eye, a pathway linked to Stargardt disease and geographic atrophy in dry age-related macular degeneration. Belite Bio raised approximately $92 million through its IPO and concurrent private placements in April 2022, and its primary operations span San Diego and Hong Kong. The firm's pipeline concentrates on Tinlarebant across multiple indications. The lead program for Stargardt disease — a rare, inherited condition causing vision loss in children and young adults — entered a pivotal Phase 3 trial (DRAGON). A second Phase 3 trial (PHOENIX) is evaluating Tinlarebant for geographic atrophy secondary to dry AMD, a much larger market with significant unmet need. The company has reported positive interim data for both programs and is actively enrolling patients across sites in the United States, Europe, and Asia. Investment reasoning hinges entirely on a single-molecule, multi-indication strategy. Belite Bio maintains a lean public-company team with its executive leadership based largely in the US and strategic operations in Hong Kong. The firm is backed by a syndicate of healthcare-focused institutional investors. In April 2024, the company announced clinical updates to both Phase 3 trials, reinforcing its timelines for topline data expected in late 2024 and 2025. This firm's structure separates it from typical venture-funded biotechs. It is an operating company publicly listed on Nasdaq (BLTE) rather than a family office or investment fund. That public-market access provides liquidity and capital-raising options unavailable to private peers, in exchange for the scrutiny and volatility that come with binary clinical-stage drug development.

## Sectors

- Biotech
- Digital Health

## Offices

- Hong Kong

## People

- Tom Lin — Chairman and CEO
- Nathan Mata — Chief Scientific Officer

## Questions

### What is Belite Bio's lead drug candidate?

Tinlarebant (LBS-008) is a once-daily oral retinol-binding protein 4 antagonist designed to reduce the accumulation of cytotoxic vitamin A byproducts in the retina. It is the sole drug candidate in the firm's pipeline, being tested in two separate Phase 3 trials for Stargardt disease and geographic atrophy.

### How is Belite Bio funded?

Belite Bio went public on the Nasdaq in April 2022. The IPO and accompanying private placements raised roughly $92 million, and the company is also backed by healthcare-specialist institutional investors. As a public company, it funds operations primarily through equity offerings.

### Where are Belite Bio's clinical trials being conducted?

The firm actively recruits patients across a global network of trial sites. Its operations and investigator footprint stretch across the United States, Europe, and Asia, with corporate presence in San Diego and Hong Kong.

## Related profiles

- [Garrett Motion](https://altss.com/profile/garrett-motion-inc)
- [Mercury General](https://altss.com/profile/mercury-general-corp)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/belite-bio-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology